



T for Texas

Friday, August 26, 2011

A couple of Texas Supreme Court developments of interest. (1) the court reversed the adverse Vioxx decision in <u>Garza</u> - holding that the plaintiffs did not provide sufficient epidemiological evidence in a low dose case. A copy of the opinion, which requires two epidemiological studies showing a relative risk of 2 or more, is available <u>here</u>.

We've <u>blogged before</u> about the adverse <u>Centocor, Inc. v. Hamilton</u>, 310 S.W.3d 476 (Tex. App. 2010), decision allowing a direct-to-consumer exception to the learned intermediary rule - and made it #4 on our <u>botton-ten worst decisions</u> for 2010. Bexis also wrote an amicus brief in the case. Well, today's <u>order list</u> (look for "cases granted") includes the Texas Supreme Court's grant of the long-pending appeal in <u>Hamilton</u>. That's a very good sign for getting rid of the only non-New Jersey decision allowing a DTC exception.